2016-03-05T00:00:00.000-05:00
transaction,-0.280431
metabolic diseases,-0.783624
pharmaceutical company,-0.55202
Mutual Fund Advisers,0.42077
strong buy rating,0.431583
JHL Capital Group,0.288224
price target,-0.415157
Asset Management LLC,0.447714
Balyasny Asset Management,0.447714
stock,0.0654083
InvestorPlace Broker Center,0.555736
average price target,-0.415157
Fund Advisers Trust,0.42077
nonabsorbed polymeric drugs,-0.55202
biopharmaceutical company,-0.567456
abnormally elevated levels,-0.712283
Janus Capital Management,0.0361691
Emerald Mutual Fund,0.42077
sell rating,0.415713
personal trading style,0.598412
Zacks Investment Research,0.314814
SVP Wilhelm Stahl,-0.237838
average rating,-0.415157
Emerald Advisers,0.285163
RLYP,-0.21548
buy rating,0.404435
research note,0.350137
senior vice president,0.213586
SVP Lance Berman,-0.323025
MarketBeat.com reports,-0.2855
Relypsa Inc Daily,0.470406
average price,0.104238
shares,0.0814344
polymeric drugs,-0.559738
non-absorbed polymeric drugs,-0.567456
concise daily summary,0.530175
research reports,-0.21548
stock broker,0.245696
company,-0.164927
Relypsa,0.157281
Capital Group LLC,0.288224
quarterly earnings data,-0.242644
quarter,0.0982268
